Cefotaxime
Formulations: - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) Indications: - Bacterial meningitis - Inflammatory and other diseases of prostate (severe) - Acute pyelonephritis (severe) - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Bacterial pneumonia (Community-acquired pneumonia - severe) - Peritoneal abscess (mild-moderate) - Peritoneal abscess (severe) - Other specified pneumonia (Hospital-acquired pneumonia) - Peritonitis (mild-moderate) - Peritonitis (severe) - Inflammatory and other diseases of prostate (mild to moderate) - Acute pyelonephritis (mild to moderate) - Sepsis without septic shock - Bacterial infection of joint - Osteomyelitis or osteitis - Bacterial infection of unspecified site Source: EML workbook import